Successful Treatment of Congenital Hyperinsulinism Due to KJNJ11 Gene Mutation with Long-Acting Release Octreotide: A Case Report from the Arab Region

Abstract

Congenital hyperinsulinism is a rare hereditary condition that is caused by various gene mutations related to the function of the pancreatic β-cells. It is characterized by dysregulation of insulin secretion leading to profound and recurrent hypoglycemia. Its clinical presentation, histology, response to treatment, and underlying genetic defects are variable making it a heterogeneous condition. Pancreatectomy is indicated in diazoxide un-responsive cases. However, surgical treatment is associated with the possibility of persistent hypoglycemia and iatrogenic diabetes. We report a 3 months old girl who presented with hyperinsulinemic hypoglycemia. She was born to consanguineous parents and had a history of four neonatal deaths in siblings. Whole exome sequencing detected a KCNJ11 variant c.350_352del p.(Phe117del) in a homozygous state. Pancreatic scan (positron emission tomography/computed tomography) showed a diffusely increased radioisotope uptake in the head and tail of the pancreas. She was resistant to diazoxide and nifedipine and was shifted to octreotide treatment through multiple daily subcutaneous injections initially. Treatment was changed to monthly depot injection of octreotide that resulted in euglycemia. She kept a normal rate of growth, insulin-like growth factor-1, and liver function. This case is an example of an alternative effective medical therapy that avoids major surgical intervention and prevents long-term complication of recurrent hypoglycemia and iatrogenic diabetes resulting after surgery.

Keywords

congenital hyperinsulinism - KCNJ11 - hypoglycemia - octreotide

Author Contributions

G.M.H. and A.Al-H. are the intensive care consultants under whom the patient was attended. They followed the patient up and provided detailed information on her progress. M.E. wrote a draft for the manuscript and provided the figures. I.S. is the surgeon who was involved in her care and led discussion over surgical treatment. A.D. advised on the medical treatment, wrote the final manuscript, liaised between authors, and submitted the article. All coauthors reviewed the submitted manuscript.

Publikationsverlauf

Artikel online veröffentlicht:
05. April 2023

• References

• 1 Alaei MR, Akbaroghli S, Keramatipour M, Alaei A. A case series: congenital hyperinsulinism. Int J Endocrinol Metab 2016; 14 (04) e37311
• 2 Dunne MJ, Kane C, Shepherd RM. et al. Familial persistent hyperinsulinemic hypoglycemia of infancy and mutations in the sulfonylurea receptor. N Engl J Med 1997; 336 (10) 703-706
• 3 Chandran S, Peng FY, Rajadurai VS. et al. Paternally inherited ABCC8 mutation causing diffuse congenital hyperinsulinism. Endocrinol Diabetes Metab Case Rep 2013; 2013: 130041
• 4 Thomas PM, Cote GJ, Wohllk N. et al. Mutations in the sulfonylurea receptor gene in familial persistent hyperinsulinemic hypoglycemia of infancy. Science 1995; 268 (5209): 426-429
• 5 Pinney SE, Ganapathy K, Bradfield J. et al. Dominant form of congenital hyperinsulinism maps to HK1 region on 10q. Horm Res Paediatr 2013; 80 (01) 18-27
• 6 Shah P, Demirbilek H, Hussain K. Persistent hyperinsulinaemic hypoglycaemia in infancy. Semin Pediatr Surg 2014; 23 (02) 76-82
• 7 Arya VB, Senniappan S, Demirbilek H. et al. Pancreatic endocrine and exocrine function in children following near-total pancreatectomy for diffuse congenital hyperinsulinism. PLoS One 2014; 9 (05) e98054
• 8 Yorifuji T, Kawakita R, Hosokawa Y. et al. Efficacy and safety of long-term, continuous subcutaneous octreotide infusion for patients with different subtypes of KATP-channel hyperinsulinism. Clin Endocrinol (Oxf) 2013; 78 (06) 891-897
• 9 Le Quan Sang K-H, Arnoux J-B, Mamoune A. et al. Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrinol 2012; 166 (02) 333-339
• 10 Al Anezi A, Mathew S, Ibrahim A. A new experience in treatment of congenital hyperinsulinism with long-acting octreotide: a case report. Endo Metab Inter J. 2016; 3 (04) 98-99
• 11 Yorifuji T. Congenital hyperinsulinism: current status and future perspectives. Ann Pediatr Endocrinol Metab 2014; 19 (02) 57-68
• 12 Rahman SA, Nessa A, Hussain K. Molecular mechanisms of congenital hyperinsulinism. J Mol Endocrinol 2015; 54 (02) R119-R129
• 13 Theodoropoulou M, Stalla GK. Somatostatin receptors: from signaling to clinical practice. Front Neuroendocrinol 2013; 34 (03) 228-252
• 14 Hosokawa Y, Kawakita R, Yokoya S. et al. Efficacy and safety of octreotide for the treatment of congenital hyperinsulinism: a prospective, open-label clinical trial and an observational study in Japan using a nationwide registry. Endocr J 2017; 64 (09) 867-880
• 15 Demirbilek H, Shah P, Arya VB. et al. Long-term follow-up of children with congenital hyperinsulinism on octreotide therapy. J Clin Endocrinol Metab 2014; 99 (10) 3660-3667
• 16 Modan-Moses D, Koren I, Mazor-Aronovitch K, Pinhas-Hamiel O, Landau H. Treatment of congenital hyperinsulinism with lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab 2011; 96 (08) 2312-2317
• 17 van der Steen I, van Albada ME, Mohnike K. et al. A multicenter experience with long-acting somatostatin analogues in patients with congenital hyperinsulinism. Horm Res Paediatr 2018; 89 (02) 82-89
• 18 Corda H, Kummer S, Welters A. et al. Treatment with long-acting lanreotide autogel in early infancy in patients with severe neonatal hyperinsulinism. Orphanet J Rare Dis 2017; 12 (01) 108